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Examining relationships between age at
diagnosis and health-related quality of life
outcomes in prostate cancer survivors
Christine J. Kurian1, Amy E. Leader2, Melissa S. Y. Thong3, Scott W. Keith4 and Charnita M. Zeigler-Johnson2*
Abstract
Background: Patient reports of health related quality of life can provide important information about the long-term
impact of prostate cancer. Because patient symptoms and function can differ by age of the survivor, the aim of our
study was to examine patient-reported quality of life and prostate symptoms by age at diagnosis among a registry of
Dutch prostate cancer survivors.
Methods: A population of 617 individuals from the Patient Reported Outcomes Following Initial Treatment and
Long-Term Evaluation of Survivorship (PROFILES) database was surveyed using the European Organization for
Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) and prostate symptom (EORTC QLQ-
PR25) scales. Age at diagnosis was the main independent variable, with three age categories: 60 years and younger, 61–
70 years, and 71 years and older. Dependent variables were the EORTC-QLQ-C30 and EORTC QLQ-PR25 scales, divided
into positive and negative outcomes. Positive measures of health-related quality of life included global health, physical
functioning, role functioning, emotional functioning, cognitive functioning, and social functioning. Negative outcomes
included fatigue, nausea, pain, dyspnea, insomnia, appetite, constipation, and diarrhea. We also assessed sexual activity,
and urinary, bowel and hormonal symptoms. Descriptive analyses included frequencies with chi-square tests and
medians with Kruskal-Wallis tests. Multivariable adjusted analyses were conducted by median regression modeling.
Results: Among the numerous scales showing some unadjusted association with age group, only two scales
demonstrated significant differences between prostate cancer patients age 71+ compared to the youngest
group (age < 61) after multivariable adjustment. On average, the oldest patients experienced an 8.3-point
lower median physical functioning score (β = − 8.3; 95% CI = − 13.9, − 2.8; p = 0.003) and a 16.7-point lower
median sexual activity score (β = − 16.7; 95% CI = − 24.7, − 8.6; p < 0.001) while controlling for BMI, marital
status, time since diagnosis, comorbidities (heart condition), Gleason score, and treatment (prostatectomy).
Conclusions: Results suggest that patient age at diagnosis should be considered among factors that contribute to
health-related quality of life outcomes for prostate cancer survivors. Implications for Cancer Survivors: A
possible reevaluation of screening recommendations may be appropriate to acknowledge age as a factor
contributing to health-related quality of life outcomes for prostate cancer survivors.
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Background
Prostate cancer is the second most common cancer
worldwide in men, with approximately 70% of new cases
diagnosed in 2012 found in developed countries [1]. The
majority of these men, however, do not die from prostate
cancer. As the number of prostate cancer survivors
increases, ensuring health-related quality of life (HRQL)
becomes increasingly important for better overall health
outcomes.
Quality of life measures encompass the physical, emo-
tional, and social domains [2]. HRQL in prostate cancer
patients has been examined in varying capacities using
diverse means of quantifying data. A cross-sectional
study using the Cancer Rehabilitation Evaluation System
(CARES) found that quality of life declined with in-
creased time for prostate cancer survivors [3]. However,
another study found that functional status scores did not
decline within one year after diagnosis for prostate
cancer [4]. Diefenbach et al. found that higher levels of
functional quality of life lead to lower levels of distress
for both those patients older and younger than 68 [5].
Although some studies [2] did not observe that age at
diagnosis predicted quality of life, other studies suggest
that age at diagnosis can have significant, varying effects
on subsequent HRQL [6–8]. Whether an earlier diagno-
sis leads to an increased propensity for further positive
lifestyle changes, or instead leads individuals to worse
health outcomes, however, is a topic of debate. Lintz and
colleagues found that patients diagnosed at a younger
age reported increasing fatigue [6]. Pinkawa et al., evalu-
ated quality of life measures in German prostate cancer
patients before treatment [7]. This study found that in-
creased patient age affected HRQL negatively for pros-
tate cancer patients that were about to undergo
treatment, particularly in the spheres of increasing urin-
ary incontinence, increasing urinary bother (including ir-
ritation and obstruction), and decreasing sexual function
with increasing age. Kikkawa and colleagues evaluated
quality of life in Japanese prostate cancer patients specif-
ically treated by high-dose rate brachytherapy combined
with external beam radiotherapy 24 months after treat-
ment [8]. Their study utilized the Medical Outcome
Study 8-items Short Form Health Survey and the EPIC
questionnaire and found that older men did not differ
significantly from younger men in outcome scores from
both questionnaires.This wide range of findings demon-
strates the variability in relating age with quality of life
in cancer patients and was thus an impetus for the study
at hand. Those diagnosed at a younger age are often at a
different health trajectory compared to those diagnosed
in the later years of life. When cancer is diagnosed at a
younger age, individuals often need to completely shift
their health behaviors, specifically by adopting more
prudent lifestyle habits and focusing on necessary
outside resources [9]. Whether this shift reflects posi-
tively upon overall HRQL has yet to be thoroughly ex-
amined. Patient reports of HRQL can provide important
information about the long-term impact of prostate can-
cer. Because patient symptoms and function can differ
by age of the survivor, the aim of our study was to exam-
ine HRQL and prostate symptoms by age at diagnosis
among a registry of Dutch prostate cancer survivors.
Methods
Setting and participants
We requested patient data from the Patient Reported
Outcomes Following Initial Treatment and Long-Term
Evaluation of Survivorship (PROFILES) database to con-
duct a secondary data analysis. PROFILES collects data
from the patients sampled from the Netherlands Cancer
Registry (NCR). This data was collected in October
2011. PROFILES is a data registry designed to address
the physical and psychosocial impact of cancer from a
population of cancer survivors [10]. Data from PRO-
FILES are available for non-commercial scientific
research purposes (www.profilesregistry.nl), subject to
study question, privacy, and confidentiality restrictions,
and registration. Participants of the study live in the
southern region of the Netherlands and were sampled
from the NCR [11]. These individuals provided written
consent to participate in the study and were invited to
complete a questionnaire, which asked various questions
pertaining to HRQL. Of 1649 patients diagnosed be-
tween 2006-2009, 1050 were still alive at the time of the
HRQL collection. Of the remaining 1050 valid individ-
uals, 695 responded to the invitation to participate in
HRQL collection, 301 did not and 54 had non-verifiable
addresses. Of the remaining 695 participants, 617 indi-
viduals had complete data in regards to the HRQL scales
and were analyzed in the current study (Fig. 1).
Study measures
European Organization for Research of Cancer quality of
life questionnaire
Health-related quality of life was assessed using the
European Organization for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC-QLQ-C30)
[12]. This self- reported questionnaire has 30 items related
to global health status/quality of life, based on five func-
tional scales and three symptom scales, to six single items
on symptoms and financial impact [9]. This particular
study assessed various scales including: global health,
physical functioning, role functioning, emotional function-
ing, cognitive functioning, and social functioning scales
(Table 1). Scores from each scale range from 0-100, with a
higher score indicating a higher health-related quality of
life. In addition to these scales, negative outcomes were
also measured, including parameters such as fatigue,
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nausea, and pain, and prostate-related symptoms (Table 1).
Prostate-related symptoms were evaluated using the
EORTC QLQ-PR25 questions which focus on sexual activ-
ity and urinary, bowel, and hormonal symptoms. Lower
scores for sexual activity and higher scores for urinary,
bowel, and hormonal scales indicated increased severity of
symptoms.
Demographic and clinical information
Socio-demographic and clinical data were also contained
in the PROFILES database. Age at diagnosis was catego-
rized as: less than and including 60 years of age, 61 to
70 years of age, and 71 years of age and older. Gleason
score was categorized as low [2–6], medium [7], and
high [8–10]. Other relevant patient information included
the stage of cancer, ranging from I-IV, and the time since
diagnosis, ranging in categories from less than 2 years to
greater than 6 years. Treatments chosen included: pros-
tatectomy, radiation therapy (external beam radiation,
brachytherapy), hormonal therapy, and watchful waiting/
active surveillance. Comorbidities, adapted from the
Self- Reported Comorbidity Questionnaire, including
heart conditions, stroke, hypertension, asthma, bron-
chitis, chronic obstructive pulmonary disease (COPD),
diabetes, ulcers, kidney disease, liver disease, anemia,
blood conditions, thyroid disease, depression, arthritis,
backache, and rheumatism, were noted [13]. Highest
education level was categorized as: lower (primary), sec-
ondary (high school and vocational), and university.
Current marital status was assessed as married/cohabit-
ing, and divorced/separated, widowed, and never mar-
ried/never cohabiting. To simplify, categories were
combined to reflect if individuals were coupled (married)
or uncoupled (not married). Smoking behavior reflected
current smokers, former smokers, and those who never
smoked. Socioeconomic status (SES) was determined by
an area-level indicator constructed by Statistics
Netherlands [14]. Dutch postal codes were each assigned
a value dependent on aggregated individual fiscal data
on monetary home value and household income. The
SES categories were then divided into low (deciles 1-3),
medium (deciles 4-7), or high (deciles 8-10) [15]. Of the
Fig. 1 Narrowing of population of interest based on availability and completeness of data per individual
Table 1 Division of QOL scales into positive vs. negative
measures
Positive Outcomes Negative Outcomes
Global Health scale Fatigue scale
Physical Functioning scale Nausea scale
Role Functioning scale Pain scale
Emotional Functioning scale Dyspnea scale
Cognitive Functioning scale Insomnia scale
Social Funtioning scale Appetite scale
Constipation scale
Diarrhea scale
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original data set containing 1649 individuals, 40 were
characterized as residing in care-providing institutions.
Ultimately these individuals were not included in the
analysis because this category does not accurately
reflect SES.
Statistical analyses
To examine the relationship between age and quality of
life, age category at diagnosis was chosen as the main
independent variable. Dependent variables were each of
the EORTC- QLQ-C30 and EORTC QLQ-PR25 scales,
divided into positive and negative outcomes. The posi-
tive measures of health- related quality of life included
global health, physical functioning, role functioning,
emotional functioning, cognitive functioning, and social
functioning. Negative outcomes included fatigue, nausea,
pain, dyspnea (difficulty in breathing), insomnia,
appetite, constipation, and diarrhea. Prostate-related
symptoms were also analyzed as negative outco-
mes.Chi-squared tests (Fisher’s exact test where appro-
priate for cells with < 5 observations) and Kruskal-Wallis
tests were performed to examine unadjusted relation-
ships between specific age categories and demographics
or other discrete variables. We conducted median
regression modeling of the scales that showed some
evidence of unadjusted associations with age group (i.e.,
p < 0.10) by the Kruskal-Wallis test. These models, con-
trolling for BMI, marital status, time since diagnosis, co-
morbidities (heart condition), Gleason score, and
treatment (prostatectomy) were constructed to adjust
for potential confounders and better characterize the
relationships between age category at diagnosis and each
modeled health-related quality of life and prostate symp-
tom scales. Four scales, (dyspnea, appetite, constipation,
and finance) showed unadjusted associations with age
group, but had at least 85% of respondents reporting
zero values. Adjusted median regression models could
not be fitted to these scales. The criterion for statistical
significance was p < 0.05.
Results
Figure 1 displays the study population, and Table 2
details demographic information and descriptive details.
Eighteen percent of respondents (N = 106) were < age 61,
50% were age 61 to 70 (n = 307), and 33% were age 71+
(N = 204). Many demographic and clinical factors dif-
fered by age group. Body mass index (BMI, p = 0.032)
and the proportion of men who were married
(p = 0.004), college educated (< 0.001), current smokers
(< 0.001), currently employed (< 0.001) or high SES
(p = 0.002) were lowest among older men (age 71+).
Higher Gleason score (p = 0.003) and comorbidities
(specifically heart conditions (p = 0.006), diabetes
(p = 0.041), kidney disease (p = 0.021), and anemia
(p = 0.040)) were significantly more common among older
men. Older men were most likely to be treated by hor-
mone therapy or active surveillance/watchful waiting.
Among younger men (age < 61), there was a greater num-
ber of years since diagnosis (p < 0.001) and they were most
likely to be treated by prostatectomy (p < 0.001).
Table 3 presents the results of non-parametric
Kruskal-Wallis tests to examine scores for differences in
HRQL and prostate symptoms by age group. Even
though the age groups have the same or almost the same
quartiles (1st, 2nd (median) and 3rd) for many of the
scales in our sample, the test is sensitive to differences
elsewhere in distributions of these scales. Significant
findings for these scales suggest that at least one of the
age-defined populations tends to have lower scale values.
We observed that older men (age 71+) tended to have
lower values for Global Health (p = 0.006), physical func-
tioning (p < 0.001) and cognitive functioning (p = 0.010).
Their scores were higher for fatigue (p = 0.003), appetite
(p = 0.002), and constipation (p < 0.001). Men age < 61
were more likely to be impacted financially compared to
older men (p = 0.002).
Prostate symptoms also varied by age. Sexual activ-
ity was lowest for men age 71+ (p < 0.001) while urin-
ary (p = 0.030) and bowel symptom scores (p = 0.011)
were higher for these men.
Among the numerous scales showing some unadjusted
association with age group, only two scales demon-
strated significant differences between prostate cancer
patients age 71+ compared to the youngest group (age
< 61) after multivariable adjustment. On average, the
oldest patients experienced an 8.3-point lower median
physical functioning score (β = − 8.3; 95% CI = − 13.9, −
2.8; p = 0.003) and 16.7 point lower median sexual activ-
ity score (β = − 16.7; 95% CI = − 24.7, − 8.6; p < 0.001)
while controlling for BMI, marital status, time since
diagnosis, comorbidities (heart condition), Gleason
score, and treatment (prostatectomy).
Discussion
This study examined relationships between the age at
diagnosis and health-related quality of life parameters. In
univariate analyses, younger men were found to have
more positive outcomes and decreasing negative out-
comes with respect to many (10/20) of the HRQL scales.
We observed a significant decrease in global health for
older men (age 71+), which was the main scale used for
the reference populations. However, we found no signifi-
cant difference in global health after adjusting for pos-
sible confounders. Multivariable models indicated that
only physical functioning and sexual activity remain sta-
tistically significant. After multivariable analysis, young
men still reported more positive scores on the physical
functioning and sexual activity. These outcomes were
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Table 2 Demographic characteristics of the PROFILES Cohort
Variable of Interest All patients
N = 617
Age Category at Diagnosis p-value
< 61 years
N = 106
61–70 years
N = 307
71+ years
N = 204
Body Mass Index [1st, 3rd quartiles] 26.3 [24.2, 28.3] 26.8 [24.8, 28.4] 26.2 [24.3, 28.4] 25.8 [23.9, 27.7] 0.032
Marital Status Not married 97 (15.8) 12 (11.3) 39 (12.8) 46 (22.8) 0.004
Married/Co-habiting 516 (84.2) 94 (88.7) 266 (87.2) 156 (77.2)
Education Lower 85 (14.0) 4 (3.8) 36 (11.8) 45 (22.5) <0.001
Secondary 366 (60.1) 70 (66.7) 176 (57.9) 120 (60.0)
University, higher 158 (25.9) 31 (29.5) 92 (30.3) 35 (17.5)
Smoking Status Never 140 (22.8) 34 (32.4) 64 (20.9) 42 (20.9) <0.001
Former 399 (65.1) 48 (45.7) 209 (68.1) 142 (70.7)
Current 74 (12.1) 23 (21.9) 34 (11.1) 17 (8.5)
Currently Employed No 512 (85.8) 56 (52.8) 274 (90.7) 182 (96.3) <0.001
Yes 85 (14.2) 50 (47.2) 28 (9.3) 7 (3.7)
SES (%) Low 98 (16.7) 15 (14.7) 35 (12.0) 48 (24.7) 0.002
Medium 238 (40.5) 39 (38.2) 120 (41.1) 79 (40.7)
High 252 (42.9) 48 (47.1) 137 (46.9) 67 (34.5)
Gleason Score (%) 2–6 329 (55.0) 63 (61.8) 178 (60.1) 88 (44.0) 0.003
7 175 (29.3) 29 (28.4) 75 (25.3) 71 (35.5)
8–10 94 (15.7) 10 (9.8) 43 (14.5) 41 (20.5)
Stage of Cancer (%) I 292 (47.9) 57 (54.8) 154 (50.3) 81 (40.5) 0.121
II 208 (34.1) 34 (32.7) 102 (33.3) 72 (36.0)
III 97 (15.9) 11 (10.6) 45 (14.7) 41 (20.5)
IV 13 (2.1) 2 (1.9) 5 (1.6) 6 (3.0)
Time since Diagnosis (years, %) < 2 10 (1.8) 1 (1.0) 5 (1.7) 4 (2.2) <0.001
2–4 280 (49.0) 35 (36.1) 143 (49.7) 102 (54.8)
4–6 272 (47.6) 54 (55.7) 139 (48.3) 79 (42.5)
> 6 9 (1.6) 7 (7.2) 1 (0.4) 1 (0.5)
Comorbidities (%) Heart Condition 124 (22.5) 15 (14.7) 56 (20.4) 53 (30.3) 0.006
Stroke 13 (2.5) 0 (0.0) 9 (3.4) 4 (2.6) 0.174
Hypertension 207 (37.6) 35 (34.7) 106 (37.9) 66 (38.8) 0.783
Asthma, Bronchitis, COPD 71 (13.2) 7 (7.0) 40 (14.6) 24 (14.6) 0.128
Diabetes 85 (15.7) 11 (10.9) 38 (14.0) 36 (21.3) 0.041
Ulcer 10 (1.9) 1 (1.0) 5 (1.9) 4 (2.5) 0.681
Kidney Disease 16 (3.0) 2 (2.0) 4 (1.5) 10 (6.1) 0.021
Liver Disease 2 (0.4) 0 (0.0) 2 (0.8) 0 (0.0) 0.693
Anemia/Blood Condition 25 (4.7) 2 (2.0) 10 (3.8) 13 (8.2) 0.040
Thyroid Disease 14 (2.6) 2 (2.0) 4 (1.5) 8 (4.9) 0.092
Depression 42 (8.0) 12 (11.9) 20 (7.5) 10 (6.3) 0.251
Arthritis 141 (26.1) 20 (19.6) 69 (25.4) 52 (31.3) 0.098
Backache 150 (28.0) 29 (28.4) 77 (28.2) 44 (27.5) 0.983
Rheumatism 42 (8.1) 7 (7.1) 24 (9.1) 11 (6.9) 0.674
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the only parameters that were significantly worse among
older patients suggesting that when other factors (co--
morbidities, marital status, tumor aggressiveness, and
treatment type) were taken into consideration, older pa-
tients generally had HRQL that was comparable to that
of younger patients.
But, we must be cautious in our interpretation that
these age-related findings are only specific to prostate
cancer survivors. In fact, changes in physical functioning
and sexual activity with advancing age may be a conse-
quence of aging. For example, a study by Mols, et al.
compared physical functioning with cancer survivors
and an age-matched normative population and did not
find significant differences [16]. In our study, we were
not able to examine underlying factors leading to better
physical and sexual functioning among younger patients.
However, it is possible that younger men with prostate
cancer are healthier at the time of diagnosis and/or that
younger men fare better through treatment compared to
older men. Generally, younger age is associated with a
higher likelihood of sexual activity and greater physical
functioning [17–19]. Poor physical functioning also
serves as a barrier to engaging in sexual activity [17].
Several studies have examined the EORTC QLQ-C30
in normative populations to determine appropriate refer-
ence values and the validity of the questionnaire. van de
Poll-Franse and colleagues examined the EORTC
QLQ-C30 in the general Dutch population (including
both men and women), finding that increased age led to
declining functional health (all scales except for emo-
tional functioning) [20]. They also discovered that older
age led to worse pain and fatigue scores. Hinz et al.
Table 2 Demographic characteristics of the PROFILES Cohort (Continued)
Variable of Interest All patients
N = 617
Age Category at Diagnosis p-value
< 61 years
N = 106
61–70 years
N = 307
71+ years
N = 204
Treatment Type (%) Prostatectomy 224 (36.7) 63 (60.0) 123 (40.5) 38 (18.8) <0.001
Radiation 278 (45.5) 41 (39.1) 148 (48.7) 89 (44.1) 0.204
Hormone Therapy 126 (20.6) 15 (14.3) 54 (17.8) 57 (28.2) 0.004
Active Surveillance/
Watchful Waiting
27 (4.4) 5 (4.8) 12 (4.0) 10 (5.0) 0.850
The bolded p-values are significant (< 0.05)
Table 3 Health-related quality of life and prostate symptom scales by age category
Median Score [1st, 3rd quartiles] < 61 years 61–70 years 71+ years p-value
Health Related Quality of Life Global Health Scale 83.3 [66.7, 91.7] 83.3 [66.7, 91.7] 83.3 [66.7, 83.3] 0.006
Physical Functioning 93.3 [80.0, 100] 93.3 [80.0, 100] 80 [66.7, 93.3] <0.001
Role Functioning 100 [66.7, 100] 100 [66.7, 100] 100 [66.7, 100] 0.053
Emotional Functioning 100 [75.0, 100] 100 [83.3, 100] 100 [83.3, 100] 0.517
Cognitive Functioning 100 [83.3, 100] 100 [83.3, 100] 83.3 [75.0, 100] 0.010
Social Functioning 100 [83.3, 100] 100 [83.3, 100] 100 [83.3, 100] 0.095
Fatigue Scale 11.1 [0, 33.3] 11.1 [0, 22.2] 22.2 [0, 33.3] 0.003
Nausea Scale 0 [0, 0] 0 [0, 0] 0 [0, 0] 0.722
Pain Scale 0 [0, 33.3] 0 [0, 16.7] 0 [0, 33.3] 0.592
Dyspnea Scale 0 [0, 33.3] 0 [0, 33.3] 0 [0, 33.3] 0.085
Insomnia Scale 0 [0, 33.3] 0 [0, 33.3] 0 [0, 33.3] 0.851
Appetite Scale 0 [0, 0] 0 [0, 0] 0 [0, 0] 0.002
Constipation Scale 0 [0, 0] 0 [0, 0] 0 [0, 0] <0.001
Diarrhea Scale 0 [0, 0] 0 [0, 0] 0 [0, 0] 0.834
Financial Scale 0 [0, 0] 0 [0, 0] 0 [0, 0] 0.002
Prostate Symptoms Sexual Activity 33.3 [16.7, 50.0] 33.3 [0, 33.3] 16.7 [0, 33.3] <0.001
Urinary Symptoms 12.5 [4.2, 20.8] 16.7 [8.3, 28.6] 16.7 [8.3, 29.2] 0.030
Bowel Symptoms 0 [0, 0] 0 [0, 8.3] 0 [0, 8.3] 0.011
Hormonal Symptoms 11.1 [5.6, 16.7] 11.1 [0, 16.7] 8.3 [0, 16.7] 0.384
Urinary aid problems 0 [0, 33.3] 0 [0, 33.3] 0 [0, 33.3] 0.791
The bolded p-values are significant (< 0.05)
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examined the use of the EORTC QLQ-C30 in the gen-
eral German population in 2011, finding that the older
populations had a significantly lower global health score
than younger populations [21]. A study by Velenik et al.
examining HRQL measures in the EORTC QLQ-C30 in
the general Slovenian population found that scores were
significantly affected by gender, age, and social class;
mean scores decreased with increasing age [22]. Com-
paring our results in Dutch prostate cancer survivors to
these reference values of normative populations, age was
a significant factor leading to decreased physical
functioning.
Among the limited studies using similar European
questionnaires in prostate cancer patients and/or survi-
vors, the impact of age at diagnosis is not fully eluci-
dated. Dabrowska-Bender and colleagues looked at
subjective quality of life in Polish prostate cancer pa-
tients diagnosed between the ages of 51-84 using the
EORTC QLQ-C30 questionnaire, and did not find sig-
nificant differences between the quality of life scores in
differing age groups [23]. Another study examining our
population of interest, Dutch prostate cancer survivors,
found that younger men reported less bodily pain and
higher physical functioning on the 36-item short form
survey (SF-36) [16]. A previous review by Blank and
Bellizzi observed that in relation to aging and the sur-
vivorship experience, younger cancer survivors experi-
enced trajectories of greater impacts (both negative and
positive) and were more likely to make health behavior
changes than survivors who are older at diagnosis [24].
The review also noted that younger survivors experi-
enced fewer comorbidities and a greater level of physical
functioning and health. However, survivors that were
older when diagnosed were less likely to change their be-
havior. Blank and Bellizzi reasoned that this may have
resulted in a higher quality of life, as a push towards
earlier detection may, for some younger individuals, lead
to increased stress and an overall negative psychological
outlook [24]. Results are still unclear whether the
long-term effects on HRQL are the same for younger
and older survivors. More research will be needed to so-
lidify any conclusions.
Sexual dysfunction, a loss of pleasure and diminution
in sexual ability and activity, is a common long-term
consequence of prostate cancer treatment. Following
treatment, many men and their partners develop sexual
dysfunction in response to erectile dysfunction and other
side effects [25]. Indeed, the men in our study who were
diagnosed at a younger age reported fewer symptoms re-
lated to sexual activity than men who were diagnosed
later in life. Sexual dysfunction influences social relation-
ships and quality of life, and while a substantial amount
of research has documented this problem in prostate
cancer survivors [26–29], less is known about the lived
experiences of the men and the impact it has on their
partners and spouses [30, 31].
Our findings also speak to the need for integration of
geriatric oncology into clinical practice, as the health
needs of older patients are not the same as those of
younger patients. Since 2005, the comprehensive geriat-
ric assessment has been advocated for senior adult on-
cology patients, defined as those aged 70 years or older
[32]. Comprehensive screening of older patients will
identify problems in sexual functioning as well as
characterize general health status, so an appropriate plan
of treatment can be formulated for all patients. Clini-
cians and other health care providers should be aware of
the impact of prostate cancer treatment on long-term
sexual health, particularly among their patients of vari-
ous age groups, and ensure that patients are connected
to the appropriate resources to address their concerns.
Appropriate social support and survivorship care plans
may facilitate communication about functional and
sexual well-being of aging prostate cancer survivors
[17, 18, 33]. With a growing number of prostate can-
cer survivors, it is important to monitor the HRQL of
patients as they continue post-treatment care.
Study limitations
Limitations existed within the analysis, which may have
contributed to or detracted from the significant associa-
tions found. The study population of men was reduced
to ensure completeness of data. This could have ex-
cluded certain data outliers that may have resulted in
otherwise unremarkable trends, resulting in selection
bias. When we compared the original sample to the
study sample, we found significant differences between
the two populations in regards to age category at diag-
nosis (p <0.001), with the original population having an
increased number of older individuals. This suggests that
the results obtained may not be applicable to widespread
populations in this preliminary stage. In particular, since
older age is generally associated with poorer HRQL, the
results may underestimate the effects of old age on
HRQL. The presence of non-respondents and unverified
addresses indicates that not all members of the study
sample were evaluated. Additionally, the cross-sectional
design contains limitations of its own because causality
cannot be readily inferred. Since the data does not con-
sider patients from a longitudinal standpoint, no com-
parison can be made between previous and current
HRQL in individuals. Relating to this, baseline data were
not available for this population so there was no means
of comparison between previous and current HRQL.
Study strengths
Completeness of the data contributed to more robust as-
sociations between the different variables. Only those
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who answered questions pertaining to the health-related
quality of life scales were included. To our knowledge,
this is the first study to examine the effects of age at
diagnosis on HRQL of Dutch prostate cancer survivors
using the EORTC QLQ-C30 and EORTC-QLQ-PR25
scales.
Conclusions
Prostate cancer patients with a younger age at diagnosis
reported the highest health- related quality of life. Men
diagnosed at a younger age showed higher levels of
physical functioning and sexual activity. Results suggest
a possible reevaluation of screening recommendations to
acknowledge patient age as a factor contributing to
health-related quality of life outcomes for prostate can-
cer survivors.
Abbreviation
HRLQ: Health-related quality of life
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